KellyEliseDooleyMD
Infectious Disease • Baltimore, MDAssistant Professor of Medicine, Johns Hopkins University School of Medicine
Dr. Dooley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287Phone+1 410-955-3100- Is this information wrong?
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 2005 - 2008- Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
Duke University School of MedicineClass of 1999
Certifications & Licensure
OR State Medical License 2002 - Present
TN State Medical License 2022 - 2025
MD State Medical License 2006 - 2022- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers Start of enrollment: 2009 Dec 01
- Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers Start of enrollment: 2010 Apr 01
- Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- Pharmacokinetic-Pharmacodynamic Evidence from a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.Velasquez, G., Huy X Ngo, Ava Y Xu, Gustavo E Velásquez, Nan Zhang, Vincent K Chang, Ekaterina V Kurbatova, William C Whitworth, Erin Sizemore, Kia Bryant, Wendy Carr,...> ;Clinical Infectious Diseases. 2024 Mar 11
- Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.Allan Kengo, Ruth Nabisere, Kamunkhwala Gausi, Joseph Musaazi, Allan Buzibye, Denis Omali, Rob Aarnoutse, Mohammed Lamorde, Derek James Sloan, Paolo Denti, Christine S...> ;Antimicrobial Agents and Chemotherapy. 2023 Nov 15
- 1 citationsUnexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin.Allan Kengo, Kamunkhwala Gausi, Ruth Nabisere, Joseph Musaazi, Allan Buzibye, Denis Omali, Rob Aarnoutse, Mohammed Lamorde, Derek James Sloan, Christine Sekaggya-Wilts...> ;Antimicrobial Agents and Chemotherapy. 2023 Nov 15
- Join now to see all
Journal Articles
- State of the Art Review of HIV‐TB Coinfection in Special PopulationsEthel D Weld, Kelly E Dooley, Clinical Pharmacology & Therapeutics
Press Mentions
Johns Hopkins School of Medicine Among Clinical Trial Sites Testing COVID-19 TherapiesNovember 18th, 2020
Johns Hopkins Researchers to Present Latest Findings on TB and HIV at CROI 2019March 7th, 2019
Tip Sheet: Johns Hopkins Researchers Present at Annual CROI MeetingMarch 1st, 2018
Grant Support
- PK/PD Issues In The Use Of New Therapies For The Treatment Of TuberculosisNational Institute Of Allergy And Infectious Diseases2009–2012
Other Languages
- French
Hospital Affiliations
Vanderbilt University Medical CenterNashville, Tennessee
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/kelly-dooley
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
